ESPU Congress 2017 - Abstract book

19–22 APRIL, 2017, BARCELONA, SPAIN

S6-8 (P without presentation)

PAEDIATRIC KIDNEY TRANSPLANTATION: A SINGLE-

CENTRE EXPERIENCE OF 16 YEARS

Anja LINGNAU

, Therese-Marie KOCH

and Beatriz BANUELOS-MARCO

1) Charité Univeritätsmedizin, Paediatric Urology, Berlin, GERMANY - 2) Charite - Universitätsmedizin Berlin, Paediatric

Nephrology, Berlin, GERMANY - 3) Charité - Universitätsmedizin Berlin, Paediatric Urology, Berlin, GERMANY

PURPOSE

Renal transplantation remains the treatment of choice for children with end-stage renal disease.

Our aim was to evaluate the effect of patient, surgical and medical factors on the surgical complica-

tions and graft function following renal transplantation in children.

MATERIAL AND METHODS

143 children and adolescent transplantations in a single centre from January 1997 to May 2013 were

assessed retrospectively. We analysed long-term survival rates and complications, and searched

for predictive parameters for graft function.

RESULTS

143 kidney transplantations were performed in 132 patients. Mean age at transplantation was

11.5±4.8 years. The percentage of living donor kidney transplants was 24.5% (35/143). Mean

donor age was 33.3±19.6 years. Rejections occurred in 44.1% (63/143). Graft failure occurred in

25% (35/143). Graft survival rates were 92.2%,85.5%,71.1% and 62.1% after 1,5,10 and 15 years

respectively.

The following variables concerning graft survival were significant statistically: Transplantation era,

donor age, High Urgency, retransplantation, postoperative use of EPO, cold ischemia time, rejec-

tions proved by biopsy and panel reactive antibodies after transplantation. (Table 1).

Overall mortality is 5.6%. Overall survival was 99.3%, 95.2%, 94.2%. 90.7%after 1,5,10 and 15 years

respectively. Retransplantation (p=0.022) and Post-Transplant-Lymphoproliferative-Disorders

(p=0.002) are significant parameters for patient survival. Infections were the main causes of death.

CONCLUSIONS

Renal transplantation in children is a safe and successful procedure. Due to new immunosup-

pressive medication, decreased number of rejections and improvement of transplant outcome and

patient outcome were seen.

Influencing factors on graft survival e.g. of donor age and condition, cold ischemia time should be

taken into account for allocating the organ.